FH-006 clinical trials
Also written FH-006.
How each study uses FH-006 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the FH-006 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- FH-006
- 2
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
BP102 (1) · Bevacizumab (1) · Adebrelimab (1) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test FH-006.
- Feb 2027A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid TumorsPhase 1/2 · Jiangsu HengRui Medicine Co., Ltd.
- Nov 2027A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerPhase 2 · Jiangsu HengRui Medicine Co., Ltd.
Studies
Open first, then newest update. How each study uses FH-006 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.RecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07790380Written as FH-006
- A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07136142Written as FH-006 for Injection
- A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07241767Written as FH-006; SHR-1316 ; SHR-8068
- Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06735144Written as FH-006